These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22269801)

  • 1. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration.
    Li XP; Xie WJ; Zhang Z; Kansara S; Jankovic J; Le WD
    Neurosignals; 2012; 20(4):223-36. PubMed ID: 22269801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.
    Zhu W; Li X; Xie W; Luo F; Kaur D; Andersen JK; Jankovic J; Le W
    Neurobiol Dis; 2010 Feb; 37(2):307-13. PubMed ID: 19818853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of iron in UPS impairment model of Parkinson's disease.
    Le W
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S158-61. PubMed ID: 24262171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
    Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
    J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
    Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
    Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
    Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W
    FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo.
    Pan T; Zhu W; Zhao H; Deng H; Xie W; Jankovic J; Le W
    Brain Res; 2008 Jul; 1222():222-9. PubMed ID: 18579122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures.
    Li X; Yang D; Li L; Peng C; Chen S; Le W
    Neurochem Int; 2007 Jun; 50(7-8):959-65. PubMed ID: 17561309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
    Zhang X; Xie W; Qu S; Pan T; Wang X; Le W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):544-9. PubMed ID: 15950935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of clusterin/apolipoprotein J in lactacystin-treated SH-SY5Y cells.
    Carreras I; Garrett-Young R; Ullman MD; Eisenhauer PB; Fine RE; Wells JM; Conn KJ
    J Neurosci Res; 2005 Feb; 79(4):495-502. PubMed ID: 15635600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration.
    Zhou ZD; Lan YH; Tan EK; Lim TM
    Free Radic Biol Med; 2010 Dec; 49(12):1856-71. PubMed ID: 20854902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
    Lewis FW; Fairooz S; Elson JL; Hubscher-Bruder V; Brandel J; Soundararajan M; Smith D; Dexter DT; Tétard D; Pienaar IS
    Arch Toxicol; 2020 Mar; 94(3):813-831. PubMed ID: 32078022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration.
    Li X; Du Y; Fan X; Yang D; Luo G; Le W
    J Neuropathol Exp Neurol; 2008 Oct; 67(10):933-44. PubMed ID: 18800014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: the synergistic role of dopamine.
    Bazzini E; Samuele A; Granelli M; Levandis G; Armentero MT; Nappi G; Blandini F
    J Cell Biochem; 2008 Feb; 103(3):877-85. PubMed ID: 17647258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies.
    Smith SR; Cooperman S; Lavaute T; Tresser N; Ghosh M; Meyron-Holtz E; Land W; Ollivierre H; Jortner B; Switzer R; Messing A; Rouault TA
    Ann N Y Acad Sci; 2004 Mar; 1012():65-83. PubMed ID: 15105256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells.
    Xu H; Jiang H; Wang J; Xie J
    J Cell Biochem; 2010 Dec; 111(6):1537-45. PubMed ID: 20872781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion.
    Yao JH; Li YH; Wang ZZ; Zhang XS; Wang YZ; Yuan JC; Zhou Q; Liu KX; Tian XF
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1102-8. PubMed ID: 17880361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
    Matsui H; Ito H; Taniguchi Y; Inoue H; Takeda S; Takahashi R
    J Neurochem; 2010 Oct; 115(1):178-87. PubMed ID: 20649841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changed iron regulation in scrapie-infected neuroblastoma cells.
    Fernaeus S; Hälldin J; Bedecs K; Land T
    Brain Res Mol Brain Res; 2005 Feb; 133(2):266-73. PubMed ID: 15710243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased levels of proteasome activity and proteasome expression in aging spinal cord.
    Keller JN; Huang FF; Markesbery WR
    Neuroscience; 2000; 98(1):149-56. PubMed ID: 10858621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.